Discover video-sourced quotes by politicians

Ron Johnson: “There's an awful lot of incentive or disincentive for doing…”

Featuring: Ron Johnson, Republican | U.S. Senate, Wisconsin

Sen. Johnson at HSGAC

Published February 25, 2016 | Video Starts at 17:27

Well, you know, I'm quite sympathetic with, you know, private sector businesses having kind of an adverse reaction to what the FDA can do to them, as well as trial lawyers as well. I mean, There's an awful lot of incentive or disincentive for doing this. And that's what we're trying to break through. What are the impediments, you know? Darcy, do you have a comment? Well, yeah, I would just add, I mean, I feel like some of this conversation is about the … (17:27–17:33)

CLAIM

Asserts that there are significant incentives or disincentives affecting drug development.

This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.

Discover more from

Ron Johnson

“The reason it takes 10 years is the approval process. And now the $2.6 billion is the latest cost.”
Sen. Johnson at HSGAC | Uploaded February 25, 2016 | 28:01-28:09
“The title is connecting patients to new and potential life saving treatments.”
Sen. Johnson at HSGAC | Uploaded February 25, 2016 | 00:10-00:16
“Darcy Olson who has certainly been at the forefront of trying to pass and is successfully passing legislation called right to try in states.”
Sen. Johnson at HSGAC | Uploaded February 25, 2016 | 00:19-00:28
“We also have a binder of 200 letters submitted to this committee in favor of us holding this hearing.”
Sen. Johnson at HSGAC | Uploaded February 25, 2016 | 02:32-02:39
“I know about this initiative. I'm fully supportive of right to try.”
Sen. Johnson at HSGAC | Uploaded February 25, 2016 | 04:24-04:30
“There's no law that prevents children being involved in clinical trials.”
Sen. Johnson at HSGAC | Uploaded February 25, 2016 | 06:13-06:17
“Members of Congress beat up on [the] FDA, they become even more risk averse.”
Sen. Johnson at HSGAC | Uploaded February 25, 2016 | 09:18-09:22
“I can't imagine having a family member with ALS knowing this seven years ago, somebody surviving this and not having access to it.”
Sen. Johnson at HSGAC | Uploaded February 25, 2016 | 10:24-10:33
“The companies themselves are concerned about having adverse results [from compassionate use].”
Sen. Johnson at HSGAC | Uploaded February 25, 2016 | 14:08-14:15
“I'm quite sympathetic with, you know, private sector businesses having kind of an adverse reaction to what the FDA can do to them.”
Sen. Johnson at HSGAC | Uploaded February 25, 2016 | 17:18-17:27
“To me that sounds like a no brainer. Let's take the, you know, the first steps here that are just so incredibly common sense.”
Sen. Johnson at HSGAC | Uploaded February 25, 2016 | 18:33-18:41
“I believe in NIH and CDC. Government can fund basic science and research.”
Sen. Johnson at HSGAC | Uploaded February 25, 2016 | 20:09-20:17
“I also believe in the private sector and innovators, individuals coming up with an idea.”
Sen. Johnson at HSGAC | Uploaded February 25, 2016 | 20:18-20:23
“As I recall, as I interpreted your testimony, the FDA was really set up almost with presumption of approval.”
Sen. Johnson at HSGAC | Uploaded February 25, 2016 | 24:02-24:10
“Because we haven't mentioned this yet, but right now we're talking about the disincentives for maybe having the FDA really stop the approval…”
Sen. Johnson at HSGAC | Uploaded February 25, 2016 | 25:46-25:56
“The free market provides an awful lot of incentives. Doctors themselves want to create the cures.”
Sen. Johnson at HSGAC | Uploaded February 25, 2016 | 27:25-27:32
“I'm not sure government is going to be able to dictate a proper incentive better than what the free market actually does.”
Sen. Johnson at HSGAC | Uploaded February 25, 2016 | 27:31-27:38